An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

Despite decades of progress, pediatric HIV continues to pose devastating challenges in regions with limited access to care. Globally, more than 100,000 children are infected with HIV each ...

Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in ...

A new study in Nature shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV, tapping into a critical window in early life that could reshape the ...

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT), a clinical-stage biotechnology company focused on cell and gene therapies for infectious diseases, today announced ...

A new study in Nature shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV, tapping into a critical window in early life that could reshape the ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering the sugars on their surface, hindering the host immune system and avoiding ...

Research Assistant Daniel O'Hagan works in the lab alongside Associate Professor Mauricio Martins, Ph.D., at The Wertheim UF Scripps Institute, in Jupiter, Florida. Martins' group has published a new ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.